Crawley JN (2000) What's wrong with my mouse? Behavioral phenotyping
of transgenic and knockout mice, pp 151–165. New York: Wiley.
Di Paola R, Uitti RJ (1996) Early detection of Parkinson's disease. Implications for treatment. Drugs Aging 9:159 –168.
Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM (2001)
Evaluation of nigrostriatal dopaminergic function in adult / and /
BDNF mutant mice. Exp Neurol 170:121–128.
Drucker-Col ́ın R, Garcia-Hernandez F (1991) A new motor test sensitive to
aging and dopaminergic function. J Neurosci Methods 39:153–161.
Dunnett SB (2003) Assessment of motor impairments in transgenic mice.
In: Mouse behavioral phenotyping (Crawley JN, ed), pp 1–12. Washington, DC: Society for Neuroscience.
Fernagut P-O, Chesselet M-F (2004) Alpha-synuclein and transgenic
mouse models. Neurobiol Dis, in press.
Fernagut PO, Diguet E, Labattu B, Tison F (2002) A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113:123–130.
Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M (2003)
Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout
mice. Neuroscience 116:1123–1130.
Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J,
Korf HW, Deller T, Braak H, Auburger G, Nussbaum RL (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci
24:419 – 429.
Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A,
Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL,
Chesselet MF, Maidment NT, Levine MS, Shen J (2003) Parkindeficient mice exhibit nigrostriatal deficits but not loss of dopaminergic
neurons. J Biol Chem 278:43628 – 43635.
Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RK
(2001) Evidence for a dissociation between MPTP toxicity and tyrosinase
activity based on congenic mouse strain susceptibility. Exp Neurol
168:116 –122.
Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS (2003) Selective loss
of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 114:123–131.
Hwang D-Y, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI,
Chesselet M-F, Kim K-S (2004) Pharmacological reversal of behavioral
deficits of Pitx3-deficient aphakia mice: implication as an animal model
of Parkinson's disease. Soc Neurosci Abstr 30:416.1.
Kolb B, Whishaw IQ (1985) Neonatal frontal lesions in hamsters impair
species-typical behaviors and reduce brain weight and neocortical thickness. Behav Neurosci 99:691–706.
Langston JW, Koller WC (1991) The next frontier in Parkinson's disease:
presymptomatic detection. Neurology 41:5–7.
Lees AJ (1992) When did Ray Kennedy's Parkinson's disease begin? Mov
Disord 7:110 –116.
Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from
alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11:2395–2407.
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002)
Effect of mutant alpha-synuclein on dopamine homeostasis in a new
human mesencephalic cell line. J Biol Chem 277:38884 –38894.
Lynch CB (1980) Response to divergent selection for nesting behavior in
Mus musculus. Genetics 96:757–765.
Marshall JF, Gotthelf T (1979) Sensory inattention in rats with 6-hydroxydopamine-induced degeneration of ascending dopaminergic neurons:
apomorphine-induced reversal of deficits. Exp Neurol 65:398 – 411.
Marshall JF, Turner BH, Teitelbaum P (1971) Sensory neglect produced by
lateral hypothalamic damage. Science 174:523–525.
Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A,
Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body
formation in alpha-synuclein mice: implications for neurodegenerative
disorders. Science 287:1265–1269.
Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful
method for evaluating the mouse movement disorder caused by striatal
dopamine depletion. J Neurosci Methods 73:45– 48.
Menalled LB, Chesselet MF (2002) Mouse models of Huntington's disease.
Trends Pharmacol Sci 23:32–39.
Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF
